Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum
Summary Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma....
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2012-03, Vol.37 (2), p.146-148 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 2 |
| container_start_page | 146 |
| container_title | Clinical and experimental dermatology |
| container_volume | 37 |
| creator | Shareef, M. S. Munro, L. R. Owen, R. G. Highet, A. S. |
| description | Summary
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma. |
| doi_str_mv | 10.1111/j.1365-2230.2011.04219.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_922501263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3376702901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4159-e9fc65b8475f47679f54eef9c51a5a755e594acfec273cfb9097eed2954c62543</originalsourceid><addsrcrecordid>eNpdkV1v0zAUhi0EYmXwF5AlhLhK8GdcX3Axla1MTDAJ0CRujOsel5Qk7uxEa_49Di1Fwje29D7vke0HIUxJSfN6uy0pr2TBGCclI5SWRDCqy_0jNDsFj9GMcKKKSvP5GXqW0pYQyqmST9EZY5RwKfQM_biNYRMhpTp0OHh8vbnAG9u2YWf7nyPuA25HaEJrsQ9NEx7qboPrzjf1vm7tCvcRbN9C1-c44t0Y1hAzu7FdHtqFNLTP0RNvmwQvjvs5-nZ1-XXxobj5vLxeXNwUTlCpC9DeVXI1F0p6oSqlvRQAXjtJrbRKSpBaWOfBMcWdX2miFcCaaSlcxaTg5-jNYe4uhvsBUm_aOjloGttBGJLRjElCWcUz-eo_chuG2OXLGSqFnHNB5zRTL4_UsGphbXYxPziO5u_XZeD1EbDJ2cZH27k6_eNklcVokrl3B-6hbmA85ZSYSaXZmsmYmYyZSaX5o9LszeLy_XTK_eLQr1MP-1Pfxl-mUlxJc_dpab4vP4qrL7d3Zsl_A1GQoOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545834181</pqid></control><display><type>article</type><title>Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Shareef, M. S. ; Munro, L. R. ; Owen, R. G. ; Highet, A. S.</creator><creatorcontrib>Shareef, M. S. ; Munro, L. R. ; Owen, R. G. ; Highet, A. S.</creatorcontrib><description>Summary
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/j.1365-2230.2011.04219.x</identifier><identifier>PMID: 22103549</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anti-Inflammatory Agents - adverse effects ; Antibodies, Monoclonal - adverse effects ; Biological and medical sciences ; Dermatology ; Disease Progression ; Hematologic and hematopoietic diseases ; Humans ; Hypergammaglobulinemia - complications ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulin A ; Immunoglobulinopathies ; Immunopathology ; Infliximab ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma - chemically induced ; Multiple Myeloma - pathology ; Precancerous Conditions - pathology ; Pyoderma Gangrenosum - drug therapy ; Skin involvement in other diseases. Miscellaneous. General aspects ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Clinical and experimental dermatology, 2012-03, Vol.37 (2), p.146-148</ispartof><rights>The Author(s). CED © 2011 British Association of Dermatologists</rights><rights>2015 INIST-CNRS</rights><rights>The Author(s). CED © 2011 British Association of Dermatologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4159-e9fc65b8475f47679f54eef9c51a5a755e594acfec273cfb9097eed2954c62543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25601190$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22103549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shareef, M. S.</creatorcontrib><creatorcontrib>Munro, L. R.</creatorcontrib><creatorcontrib>Owen, R. G.</creatorcontrib><creatorcontrib>Highet, A. S.</creatorcontrib><title>Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.</description><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Disease Progression</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Hypergammaglobulinemia - complications</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infliximab</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - chemically induced</subject><subject>Multiple Myeloma - pathology</subject><subject>Precancerous Conditions - pathology</subject><subject>Pyoderma Gangrenosum - drug therapy</subject><subject>Skin involvement in other diseases. Miscellaneous. General aspects</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV1v0zAUhi0EYmXwF5AlhLhK8GdcX3Axla1MTDAJ0CRujOsel5Qk7uxEa_49Di1Fwje29D7vke0HIUxJSfN6uy0pr2TBGCclI5SWRDCqy_0jNDsFj9GMcKKKSvP5GXqW0pYQyqmST9EZY5RwKfQM_biNYRMhpTp0OHh8vbnAG9u2YWf7nyPuA25HaEJrsQ9NEx7qboPrzjf1vm7tCvcRbN9C1-c44t0Y1hAzu7FdHtqFNLTP0RNvmwQvjvs5-nZ1-XXxobj5vLxeXNwUTlCpC9DeVXI1F0p6oSqlvRQAXjtJrbRKSpBaWOfBMcWdX2miFcCaaSlcxaTg5-jNYe4uhvsBUm_aOjloGttBGJLRjElCWcUz-eo_chuG2OXLGSqFnHNB5zRTL4_UsGphbXYxPziO5u_XZeD1EbDJ2cZH27k6_eNklcVokrl3B-6hbmA85ZSYSaXZmsmYmYyZSaX5o9LszeLy_XTK_eLQr1MP-1Pfxl-mUlxJc_dpab4vP4qrL7d3Zsl_A1GQoOg</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Shareef, M. S.</creator><creator>Munro, L. R.</creator><creator>Owen, R. G.</creator><creator>Highet, A. S.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum</title><author>Shareef, M. S. ; Munro, L. R. ; Owen, R. G. ; Highet, A. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4159-e9fc65b8475f47679f54eef9c51a5a755e594acfec273cfb9097eed2954c62543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Disease Progression</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Hypergammaglobulinemia - complications</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infliximab</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - chemically induced</topic><topic>Multiple Myeloma - pathology</topic><topic>Precancerous Conditions - pathology</topic><topic>Pyoderma Gangrenosum - drug therapy</topic><topic>Skin involvement in other diseases. Miscellaneous. General aspects</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shareef, M. S.</creatorcontrib><creatorcontrib>Munro, L. R.</creatorcontrib><creatorcontrib>Owen, R. G.</creatorcontrib><creatorcontrib>Highet, A. S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shareef, M. S.</au><au>Munro, L. R.</au><au>Owen, R. G.</au><au>Highet, A. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2012-03</date><risdate>2012</risdate><volume>37</volume><issue>2</issue><spage>146</spage><epage>148</epage><pages>146-148</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22103549</pmid><doi>10.1111/j.1365-2230.2011.04219.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2012-03, Vol.37 (2), p.146-148 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_922501263 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Anti-Inflammatory Agents - adverse effects Antibodies, Monoclonal - adverse effects Biological and medical sciences Dermatology Disease Progression Hematologic and hematopoietic diseases Humans Hypergammaglobulinemia - complications Immunodeficiencies. Immunoglobulinopathies Immunoglobulin A Immunoglobulinopathies Immunopathology Infliximab Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multiple Myeloma - chemically induced Multiple Myeloma - pathology Precancerous Conditions - pathology Pyoderma Gangrenosum - drug therapy Skin involvement in other diseases. Miscellaneous. General aspects Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T07%3A30%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progression%20of%20IgA%20gammopathy%20to%20myeloma%20following%20infliximab%20treatment%20for%20pyoderma%20gangrenosum&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Shareef,%20M.%20S.&rft.date=2012-03&rft.volume=37&rft.issue=2&rft.spage=146&rft.epage=148&rft.pages=146-148&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1111/j.1365-2230.2011.04219.x&rft_dat=%3Cproquest_pubme%3E3376702901%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1545834181&rft_id=info:pmid/22103549&rfr_iscdi=true |